BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 9544686)

  • 1. Radioiodine treatment outcomes in thyroid glands previously irradiated for Graves' hyperthyroidism.
    Leslie WD; Peterdy AE; Dupont JO
    J Nucl Med; 1998 Apr; 39(4):712-6. PubMed ID: 9544686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term follow-up study of radioiodine treatment of hyperthyroidism.
    Metso S; Jaatinen P; Huhtala H; Luukkaala T; Oksala H; Salmi J
    Clin Endocrinol (Oxf); 2004 Nov; 61(5):641-8. PubMed ID: 15521969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radioiodine therapy compared in patients with toxic nodular or Graves' hyperthyroidism.
    Franklyn JA; Daykin J; Holder R; Sheppard MC
    QJM; 1995 Mar; 88(3):175-80. PubMed ID: 7767667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant lithium improves the efficacy of radioactive iodine treatment in Graves' and toxic nodular disease.
    Martin NM; Patel M; Nijher GM; Misra S; Murphy E; Meeran K
    Clin Endocrinol (Oxf); 2012 Oct; 77(4):621-7. PubMed ID: 22443227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What influences early hypothyroidism after radioiodine treatment for Graves' hyperthyroidism?
    Vijayakumar V; Ali S; Nishino T; Nusynowitz M
    Clin Nucl Med; 2006 Nov; 31(11):688-9. PubMed ID: 17053385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term carbimazole intake does not affect success rate of radioactive 131Iodine in treatment of Graves' hyperthyroidism.
    El Refaei SM; Shawkat W
    Nucl Med Commun; 2008 Jul; 29(7):642-8. PubMed ID: 18528187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High dose of (131)I therapy for the treatment of hyperthyroidism caused by Graves' disease.
    Alexander EK; Larsen PR
    J Clin Endocrinol Metab; 2002 Mar; 87(3):1073-7. PubMed ID: 11889166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Radioiodine treatment of hyperthyroidism using a simplified dosimetric approach. Clinical results].
    Giovanella L; De Palma D; Ceriani L; Vanoli P; Garancini S; Tordiglione M; Tarolo GL
    Radiol Med; 2000 Dec; 100(6):480-3. PubMed ID: 11307510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment of hyperthyroidism caused by Graves' disease or toxic multinodular goitre by radioiodine: over 80% cure retrospectively after one calculated dose].
    Bakker SC; Zanin DE; Zweers EJ
    Ned Tijdschr Geneeskd; 2002 Sep; 146(39):1837-41. PubMed ID: 12382370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of propylthiouracil on subsequent radioactive iodine therapy in Graves' disease.
    Hancock LD; Tuttle RM; LeMar H; Bauman J; Patience T
    Clin Endocrinol (Oxf); 1997 Oct; 47(4):425-30. PubMed ID: 9404440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radioiodine therapy in hyperthyroidism: inverse correlation of pretherapeutic iodine uptake level and post-therapeutic outcome.
    Walter MA; Christ-Crain M; Eckard B; Schindler C; Nitzsche EU; Müller-Brand J; Müller B
    Eur J Clin Invest; 2004 May; 34(5):365-70. PubMed ID: 15147334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Characterization of therapy failures in radioiodine therapy of Graves' disease without simultaneous antithyroid agents].
    Sabri O; Zimny M; Schreckenberger M; Reinartz P; Nowak B; Ostwald E; Schäfer W; Block S; Setani K; Büll U
    Nuklearmedizin; 2001 Feb; 40(1):1-6. PubMed ID: 11373933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determination of the optimal minimum radioiodine dose in patients with Graves' disease: a clinical outcome study.
    Howarth D; Epstein M; Lan L; Tan P; Booker J
    Eur J Nucl Med; 2001 Oct; 28(10):1489-95. PubMed ID: 11685491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A predictive mathematical model for the calculation of the final mass of Graves' disease thyroids treated with 131I.
    Traino AC; Di Martino F; Grosso M; Monzani F; Dardano A; Caraccio N; Mariani G; Lazzeri M
    Phys Med Biol; 2005 May; 50(9):2181-91. PubMed ID: 15843745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in thyroid volume in response to radioactive iodine for Graves' hyperthyroidism correlated with activity of thyroid-stimulating antibody and treatment outcome.
    Murakami Y; Takamatsu J; Sakane S; Kuma K; Ohsawa N
    J Clin Endocrinol Metab; 1996 Sep; 81(9):3257-60. PubMed ID: 8784079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radioactive iodine therapy for pediatric Graves' disease: a single-center experience over a 10-year period.
    Kaplowitz PB; Jiang J; Vaidyanathan P
    J Pediatr Endocrinol Metab; 2020 Mar; 33(3):383-389. PubMed ID: 31603857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Salivary gland side effects commonly develop several weeks after initial radioactive iodine ablation.
    Grewal RK; Larson SM; Pentlow CE; Pentlow KS; Gonen M; Qualey R; Natbony L; Tuttle RM
    J Nucl Med; 2009 Oct; 50(10):1605-10. PubMed ID: 19759114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radioactive iodine therapy in Graves' hyperthyroidism: a prospective study from a tertiary referral centre in north India.
    Sankar R; Sekhri T; Sripathy G; Walia RP; Jain SK
    J Assoc Physicians India; 2005 Jul; 53():603-6. PubMed ID: 16190128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radioactive iodine in the treatment of Graves' disease.
    Al-Kaabi JM; Hussein SS; Bukheit CS; Woodhouse NJ; Elshafie OT; Bererhi H
    Saudi Med J; 2002 Sep; 23(9):1049-53. PubMed ID: 12370710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Radioiodine therapy of recurrent hyperthyroidism in patients previously treated for diffuse toxic goiter with subtotal surgery].
    Vestergaard H; Laurberg P
    Ugeskr Laeger; 1993 Aug; 155(31):2403-5. PubMed ID: 8346592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.